Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prediction-aided tapering of biologic therapy in rheumatoid arthritis
NL-OMON56102Recruiting
- Sponsor
- ZonMw
- Start
- Oct 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of adalimumab, certolizumab pegol, golimumab, infliximab, etanercept and 3 more in rheumatoid arthritis (RA) (2 arms), sponsored by ZonMw. Primary endpoint: Mean number of flares per patient over 18 months. Started Oct 2021; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON56102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56102.